Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial

por Binkley, N., Bone, H., Gilligan, J. P., Krause, D. S.
Publicado 2014

Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation

por Bone, H. G., Walter, M. A., Hurley, M. E., Epstein, S.
Publicado 2017

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

por Barrett-Connor, E., Swern, A. S., Hustad, C. M., Bone, H. G., Liberman, U. A., Papapoulos, S., Wang, H., de Papp, A., Santora, A. C.
Publicado 2011

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

por Kendler, D. L., Chines, A., Brandi, M. L., Papapoulos, S., Lewiecki, E. M., Reginster, J-Y., Muñoz Torres, M., Wang, A., Bone, H. G.
Publicado 2018

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

por Kendler, D.L., Bone, H.G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S., Dinavahi, R.V., Libanati, C., Grauer, A.
Publicado 2019

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

por Bone, H. G., Dempster, D. W., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., Verbruggen, N., Leung, A. T., Lombardi, A.
Publicado 2014

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture T...

por Bone, H. G., Dempster, D. W., Eisman, J. A., Greenspan, S. L., McClung, M. R., Nakamura, T., Papapoulos, S., Shih, W. J., Rybak-Feiglin, A., Santora, A. C., Verbruggen, N., Leung, A. T., Lombardi, A.
Publicado 2015

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

por Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, C., Wagman, R. B., Cummings, S. R.
Publicado 2016

Epidemiology of severe sepsis and septic shock in Germany: results from the German 'Prevalence' study

por Brunkhorst, FM, Engel, C, Reinhart, K, Bone, H-G, Brunkhorst, R, Burchardi, H, Eckhardt, K-U, Forst, H, Gerlach, H, Grond, S, Gründling, M, Huhle, G, Oppert, M, Olthoff, D, Quintel, M, Ragaller, M, Rossaint, R, Seeger, W, Stüber, F, Weiler, N, Welte, T, Loeffler, M
Publicado 2005

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

por Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.
Publicado 2015

Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German I...

por Reinhart, K., Brunkhorst, F. M., Bone, H.-G., Bardutzky, J., Dempfle, C.-E., Forst, H., Gastmeier, P., Gerlach, H., Gründling, M., John, S., Kern, W., Kreymann, G., Krüger, W., Kujath, P., Marggraf, G., Martin, J., Mayer, K., Meier-Hellmann, A., Oppert, M., Putensen, C., Quintel, M., Ragaller, M., Rossaint, R., Seifert, H., Spies, C., Stüber, F., Weiler, N., Weimann, A., Werdan, K., Welte, T.
Publicado 2010